The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl Borrebaeck

Carl Borrebaeck

Professor

Carl Borrebaeck

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Author

  • Carl A K Borrebaeck
  • Ann-Christin Malmborg
  • Mats Ohlin

Summary, in English

Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.

Department/s

  • Department of Immunotechnology

Publishing year

1993

Language

English

Pages

477-479

Publication/Series

Immunology Today

Volume

14

Issue

10

Document type

Journal article

Publisher

Elsevier

Status

Published

ISBN/ISSN/Other

  • ISSN: 0167-5699